comparemela.com

Latest Breaking News On - Multiple ascending dose - Page 4 : comparemela.com

Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis

GHENT, Belgium, December 14, 2023 Agomab Therapeutics NV (‘Agomab’) today announced that it has dosed the first subject in a first-in-human Phase 1 clinical study of AGMB-447, an inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβRI or ALK5). The study is evaluating AGMB-447 in healthy subjects and in patients with idiopathic pulmonary fibrosis (IPF).

Gretchen schweitzerTim knotnerusTrophic communicationsAgomab therapeuticsSingle ascending doseMultiple ascending doseChief development officerIdiopathic pulmonary fibrosisFibrostenosing crohnIdiopathic pulmonaryTransforming growth factorHepatocyte growth factorStephanie mayLung transplantLung diseasesBusiness wire

Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes At Week 26, 22 weeks after the last dose of BMF-219,.

United statesExchange commissionSecurities exchangeClinical updateMultiple ascending doseGlycemic dataPharmacokinetic dataEx vivo human islet dataSecurities actSecurities exchange actExchange actBiomea fusion

Geneoscopy and Adiso Therapeutics Announce Strategic Collaboration to Investigate New Therapeutic Options for Patients with Inflammatory Bowel Disease

ST. LOUIS, Mo. & CONCORD, Mass. (BUSINESS WIRE) Dec 5, 2023

United statesUniversity of massachusettsAndrea sampsonCarrie mendivil jiScott megaffinCollin beloinSarah sutton liza sullivanAndrew barnellSampson public relations groupUniversity of edinburgh centre for inflammation researchMicrobiome instituteGeneoscopy incUniversity college corkGilmartin groupAdiso therapeutics incUniversity of massachusetts chan medical school

Geneoscopy and Adiso Therapeutics Announce Strategic Collaboration to Investigate New Therapeutic Op

Adiso to Utilize Noninvasive RNA Technology Developed by Geneoscopy as a Precision Immunology Measure in ADS051 Phase 2 IBD TrialST. LOUIS, Mo. & CONCORD, Mass. (BUSINESS WIRE) Geneoscopy, Inc., a life sciences company focused on developing noninvasive diagnostic and precision medicine tools for gastrointestinal h.

United statesAndrea sampsonSarah sutton liza sullivanScott megaffinCarrie mendivil jiCollin beloinAndrew barnellMicrobiome instituteUniversity college corkSampson public relations groupGilmartin groupUniversity of edinburgh centre for inflammation researchUniversity of massachusetts chan medical schoolGeneoscopy incAdiso therapeutics incUtilize noninvasive

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides Seite 1

28.11.2023 - SHELTON, CT / ACCESSWIRE / November 28, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the Company ), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the . Seite 1

Karveer meditechAdverse events foundHealthy volunteers cohortsSingle ascending doseMultiple ascending doseMultiple ascending dose clinical trialHealthy volunteers was completedExecutive chairman

vimarsana © 2020. All Rights Reserved.